HUP0202469A3 - Cell adhesion inhibitor compound and pharmaceutical composition containing thereof - Google Patents
Cell adhesion inhibitor compound and pharmaceutical composition containing thereofInfo
- Publication number
- HUP0202469A3 HUP0202469A3 HU0202469A HUP0202469A HUP0202469A3 HU P0202469 A3 HUP0202469 A3 HU P0202469A3 HU 0202469 A HU0202469 A HU 0202469A HU P0202469 A HUP0202469 A HU P0202469A HU P0202469 A3 HUP0202469 A3 HU P0202469A3
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical composition
- composition containing
- cell adhesion
- inhibitor compound
- adhesion inhibitor
- Prior art date
Links
- 230000021164 cell adhesion Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14884599P | 1999-08-13 | 1999-08-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0202469A2 HUP0202469A2 (hu) | 2002-11-28 |
HUP0202469A3 true HUP0202469A3 (en) | 2004-06-28 |
Family
ID=22527673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0202469A HUP0202469A3 (en) | 1999-08-13 | 2000-08-14 | Cell adhesion inhibitor compound and pharmaceutical composition containing thereof |
Country Status (32)
Country | Link |
---|---|
US (3) | US6630503B1 (hu) |
EP (2) | EP1265606B9 (hu) |
JP (1) | JP2003506491A (hu) |
KR (1) | KR100720907B1 (hu) |
CN (1) | CN1377268A (hu) |
AT (1) | ATE343383T1 (hu) |
AU (1) | AU780610B2 (hu) |
BG (1) | BG65755B1 (hu) |
BR (1) | BR0013248A (hu) |
CA (1) | CA2380817A1 (hu) |
CY (1) | CY1105912T1 (hu) |
CZ (1) | CZ2002518A3 (hu) |
DE (1) | DE60031577T2 (hu) |
DK (1) | DK1265606T3 (hu) |
EA (1) | EA005578B1 (hu) |
EE (1) | EE200200070A (hu) |
ES (1) | ES2270868T3 (hu) |
GE (2) | GEP20063956B (hu) |
HK (1) | HK1051500A1 (hu) |
HU (1) | HUP0202469A3 (hu) |
IL (2) | IL148014A0 (hu) |
IS (1) | IS6257A (hu) |
MX (1) | MXPA02001449A (hu) |
NO (1) | NO324044B1 (hu) |
NZ (1) | NZ517011A (hu) |
PL (1) | PL354063A1 (hu) |
PT (1) | PT1265606E (hu) |
RS (1) | RS50470B (hu) |
SK (1) | SK287075B6 (hu) |
UA (1) | UA75581C2 (hu) |
WO (1) | WO2001012186A1 (hu) |
ZA (1) | ZA200201158B (hu) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
JP2003506491A (ja) * | 1999-08-13 | 2003-02-18 | バイオジェン インコーポレイテッド | 細胞接着インヒビター |
DE10006453A1 (de) * | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
RU2290403C2 (ru) | 2000-12-28 | 2006-12-27 | Дайити Фармасьютикал Ко., Лтд. | Ингибиторы vla-4 |
JP2002201168A (ja) * | 2000-12-28 | 2002-07-16 | Kaken Pharmaceut Co Ltd | シクロヘキサン誘導体 |
JP2004526733A (ja) * | 2001-03-20 | 2004-09-02 | メルク エンド カムパニー インコーポレーテッド | 強力な細胞接着阻害剤としての置換n−アリールスルホニル−プロリン誘導体 |
US6663489B2 (en) | 2001-08-24 | 2003-12-16 | Igt | Gaming device having an award distributor and an award accumulator bonus game |
ES2197003B1 (es) * | 2002-04-08 | 2005-03-16 | J. URIACH & CIA S.A. | Nuevos compuestos antagonistas de integrinas alfa. |
TWI340134B (en) | 2003-07-24 | 2011-04-11 | Daiichi Seiyaku Co | Cyclohexanecarboxylic acids |
CA2554188A1 (en) * | 2004-01-23 | 2005-08-04 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
NZ588839A (en) * | 2004-07-08 | 2012-09-28 | Elan Pharm Inc | Multivalent vla-4 antagonists comprising polyethylene glycol moieties |
US7196112B2 (en) * | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
US7915316B2 (en) * | 2005-08-22 | 2011-03-29 | Allergan, Inc | Sulfonamides |
EP2407453A1 (en) | 2005-09-27 | 2012-01-18 | Shionogi & Co., Ltd. | PGD2 receptor antagonist |
DK2623113T3 (en) * | 2005-11-09 | 2017-07-17 | Onyx Therapeutics Inc | Enzyme inhibition compound |
WO2008017025A2 (en) * | 2006-08-02 | 2008-02-07 | Genzyme Corporation | Combination therapy |
TW200817319A (en) | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
AU2008219007A1 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
CA2721093A1 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
AU2016257997A1 (en) | 2015-05-05 | 2017-11-09 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
JP6838004B2 (ja) | 2015-06-11 | 2021-03-03 | リセラ・コーポレイションLycera Corporation | RORγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物 |
US10836720B2 (en) | 2016-04-01 | 2020-11-17 | The Regents Of The University Of California | Inhibitors of integrin alpha 5 beta 1 and methods of use |
CN109721605B (zh) * | 2017-10-31 | 2022-03-11 | 维眸生物科技(上海)有限公司 | 一种免疫细胞迁徙抑制剂 |
US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
EP3873884A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
JP7491996B2 (ja) | 2019-08-14 | 2024-05-28 | ギリアード サイエンシーズ, インコーポレイテッド | α4β7インテグリンの阻害のための化合物 |
KR20240035513A (ko) | 2021-07-09 | 2024-03-15 | 알리고스 테라퓨틱스 인코포레이티드 | 항바이러스 화합물 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1149971B (it) | 1979-06-11 | 1986-12-10 | Syntex Inc | Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante |
US4725583A (en) | 1985-01-23 | 1988-02-16 | Abbott Laboratories | Functionalized peptidylaminoalcohols |
US4826815A (en) | 1985-05-17 | 1989-05-02 | Abbott Laboratories | Renin inhibiting compounds |
GB2218102B (en) | 1988-04-08 | 1992-09-16 | Sandoz Ltd | Calcitonin peptide derivatives |
DE68901431D1 (de) | 1988-07-21 | 1992-06-11 | Pfizer | Verfahren zur herstellung substituierter guanylthioharnstoffe. |
US4908360A (en) | 1988-11-14 | 1990-03-13 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aminoalkyl-3-oxysubstituted-4-aryl-1,3,4,5-tetrahydro-2H-1,3-benzodiazepine-2-ones |
US5272263A (en) | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
US5196404B1 (en) | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
WO1991009837A1 (en) | 1989-12-22 | 1991-07-11 | Commonwealth Scientific And Industrial Research Organisation | Amino acids, peptides or derivatives thereof coupled to fats |
CA2043741C (en) | 1990-06-07 | 2003-04-01 | Kiyofumi Ishikawa | Endothelin antagonistic peptide derivatives |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US5260277A (en) | 1990-09-10 | 1993-11-09 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
WO1992008464A1 (en) | 1990-11-15 | 1992-05-29 | Tanabe Seiyaku Co. Ltd. | Substituted urea and related cell adhesion modulation compounds |
WO1992022323A1 (en) | 1991-06-11 | 1992-12-23 | Center For Blood Research, Inc. | Intercellular adhesion molecule-3 and its binding ligands |
DE69226820T2 (de) | 1991-06-21 | 1999-05-12 | Merck & Co Inc | Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen |
US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
WO1993009795A1 (en) | 1991-11-22 | 1993-05-27 | Yeda Research And Development Co. Ltd. | Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them |
AU3420693A (en) | 1991-12-24 | 1993-07-28 | Fred Hutchinson Cancer Research Center | Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv |
DE4212304A1 (de) | 1992-04-13 | 1993-10-14 | Cassella Ag | Asparaginsäurederivate, ihre Herstellung und Verwendung |
IL102646A (en) | 1992-07-26 | 1996-05-14 | Yeda Res & Dev | Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them |
WO1994015958A2 (en) | 1993-01-08 | 1994-07-21 | Tanabe Seiyaku Co., Ltd. | Peptide inhibitors of cell adhesion |
US5314902A (en) | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
DE4309867A1 (de) | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
DE69427907T2 (de) | 1993-04-09 | 2002-04-04 | Toyama Chemical Co Ltd | Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen |
US5770573A (en) | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5434188A (en) | 1994-03-07 | 1995-07-18 | Warner-Lambert Company | 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV |
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
US6248713B1 (en) * | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
JP2000501105A (ja) * | 1995-12-22 | 2000-02-02 | デュポン ファーマシューティカルズ カンパニー | 新規なインテグリン受容体アンタゴニスト |
US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
WO1997048395A1 (en) * | 1996-06-19 | 1997-12-24 | Du Pont Pharmaceuticals Company | Iontophoretic delivery of integrin inhibitors |
CZ298089B6 (cs) | 1996-07-25 | 2007-06-20 | Biogen Idec Ma Inc. | Inhibitory bunecné adheze, zpusob jejich prípravya farmaceutické prostredky s jejich obsahem |
DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
AU6780398A (en) * | 1997-03-28 | 1998-10-22 | Du Pont Merck Pharmaceutical Company, The | Heterocyclic integrin inhibitor prodrugs |
DE69833654T2 (de) | 1997-05-29 | 2006-12-14 | Merck & Co., Inc. (A New Jersey Corp.) | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
EP0998282A4 (en) | 1997-05-29 | 2000-08-30 | Merck & Co Inc | SULFAMIDES FOR USE AS CELL ADHESION INHIBITORS |
CA2291778A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
DK0991619T3 (da) * | 1997-06-23 | 2003-12-29 | Tanabe Seiyaku Co | Inhibitorer af alfa 4-beta 1-medieret celleadhæsion |
CN1133648C (zh) * | 1997-07-31 | 2004-01-07 | 伊兰药品公司 | 抑制vla-4介导的白细胞粘附的取代的苯丙氨酸型化合物 |
HUP0003921A3 (en) * | 1997-07-31 | 2001-03-28 | Wyeth Corp | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use |
KR20010022406A (ko) | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Vla-4에 의해 매개되는 백혈구 유착을 억제하는디펩타이드 및 관련 화합물 |
AU8678698A (en) | 1997-07-31 | 1999-02-22 | American Home Products Corporation | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
BR9811599A (pt) * | 1997-07-31 | 2000-09-19 | Elan Pharm Inc | Compostos de dipetìdeo que inibem adesão de leucócito mediada por vla-4 |
CA2290750A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
HU229362B1 (en) * | 1997-08-22 | 2013-11-28 | Hoffmann La Roche | N-alkanoylphenylalanine derivatives |
ES2214728T3 (es) * | 1997-08-22 | 2004-09-16 | F. Hoffmann-La Roche Ag | Derivados de n-aroilfenilalanina. |
DE19741235A1 (de) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
AR013693A1 (es) * | 1997-10-23 | 2001-01-10 | Uriach & Cia Sa J | Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria |
SK5462000A3 (en) * | 1997-10-31 | 2001-02-12 | Aventis Pharma Ltd | Substituted anilides |
WO1999026923A1 (en) | 1997-11-20 | 1999-06-03 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
WO1999026922A1 (en) | 1997-11-21 | 1999-06-03 | Merck & Co., Inc. | Substituted pyrrole derivatives as cell adhesion inhibitors |
US6645939B1 (en) * | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
ES2221227T3 (es) | 1997-11-24 | 2004-12-16 | MERCK & CO., INC. | Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular. |
AU1523199A (en) * | 1997-11-26 | 1999-06-15 | Du Pont Pharmaceuticals Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as alphavbeta3 antagonists |
US6197794B1 (en) * | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6329372B1 (en) * | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
EP1056714B1 (en) * | 1998-02-26 | 2004-08-11 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
EP1063982B1 (en) * | 1998-03-27 | 2007-02-14 | Genentech, Inc. | Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders |
PL198189B1 (pl) | 1998-05-28 | 2008-06-30 | Biogen Idec Ma | (R)-N-{[4-{[(2-metylofenyloamino)-karbonylo]amino}fenylo]acetylo}-L-prolilo-3-metylo]-ß-alanina, jej zastosowanie i kompozycja farmaceutyczna ją zawierająca |
TW591026B (en) * | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
US6303625B1 (en) * | 1998-07-27 | 2001-10-16 | Ortho-Mcneil Pharmaceutical, Inc. | Triazolopyridines for the treatment of thrombosis disorders |
US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
AU2209500A (en) * | 1998-12-22 | 2000-07-12 | Pharmacia & Upjohn Company | Inhibitors of alpha4beta1 mediated cell adhesion |
EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
PL349463A1 (en) * | 1999-02-18 | 2002-07-29 | Hoffmann La Roche | Phenylalaninol derivatives |
JP2003506491A (ja) * | 1999-08-13 | 2003-02-18 | バイオジェン インコーポレイテッド | 細胞接着インヒビター |
JP2001089448A (ja) * | 1999-09-24 | 2001-04-03 | Yamanouchi Pharmaceut Co Ltd | アミド誘導体 |
US7196112B2 (en) * | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
-
2000
- 2000-08-14 JP JP2001516532A patent/JP2003506491A/ja active Pending
- 2000-08-14 HU HU0202469A patent/HUP0202469A3/hu unknown
- 2000-08-14 GE GE5468A patent/GEP20063956B/en unknown
- 2000-08-14 RS YUP-98/02A patent/RS50470B/sr unknown
- 2000-08-14 EP EP00959232A patent/EP1265606B9/en not_active Expired - Lifetime
- 2000-08-14 CN CN00813728A patent/CN1377268A/zh active Pending
- 2000-08-14 KR KR1020027001850A patent/KR100720907B1/ko not_active IP Right Cessation
- 2000-08-14 CA CA002380817A patent/CA2380817A1/en not_active Abandoned
- 2000-08-14 US US09/638,652 patent/US6630503B1/en not_active Expired - Fee Related
- 2000-08-14 NZ NZ517011A patent/NZ517011A/en unknown
- 2000-08-14 IL IL14801400A patent/IL148014A0/xx unknown
- 2000-08-14 CZ CZ2002518A patent/CZ2002518A3/cs unknown
- 2000-08-14 DK DK00959232T patent/DK1265606T3/da active
- 2000-08-14 MX MXPA02001449A patent/MXPA02001449A/es active IP Right Grant
- 2000-08-14 AT AT00959232T patent/ATE343383T1/de not_active IP Right Cessation
- 2000-08-14 GE GE4744A patent/GEP20053477B/en unknown
- 2000-08-14 PL PL00354063A patent/PL354063A1/xx not_active Application Discontinuation
- 2000-08-14 PT PT00959232T patent/PT1265606E/pt unknown
- 2000-08-14 AU AU70586/00A patent/AU780610B2/en not_active Ceased
- 2000-08-14 EA EA200200253A patent/EA005578B1/ru not_active IP Right Cessation
- 2000-08-14 BR BR0013248-9A patent/BR0013248A/pt not_active Application Discontinuation
- 2000-08-14 ES ES00959232T patent/ES2270868T3/es not_active Expired - Lifetime
- 2000-08-14 EE EEP200200070A patent/EE200200070A/xx unknown
- 2000-08-14 SK SK215-2002A patent/SK287075B6/sk not_active IP Right Cessation
- 2000-08-14 DE DE60031577T patent/DE60031577T2/de not_active Expired - Lifetime
- 2000-08-14 EP EP06021333A patent/EP1741428A3/en not_active Withdrawn
- 2000-08-14 UA UA2002032010A patent/UA75581C2/uk unknown
- 2000-08-14 WO PCT/US2000/022285 patent/WO2001012186A1/en active IP Right Grant
-
2002
- 2002-01-31 IS IS6257A patent/IS6257A/is unknown
- 2002-02-05 IL IL148014A patent/IL148014A/en not_active IP Right Cessation
- 2002-02-11 ZA ZA200201158A patent/ZA200201158B/en unknown
- 2002-02-13 NO NO20020725A patent/NO324044B1/no not_active IP Right Cessation
- 2002-03-11 BG BG106510A patent/BG65755B1/bg unknown
-
2003
- 2003-05-27 HK HK03103786A patent/HK1051500A1/xx not_active IP Right Cessation
- 2003-10-03 US US10/677,756 patent/US7034043B2/en not_active Expired - Fee Related
-
2006
- 2006-02-27 US US11/362,043 patent/US20060166961A1/en not_active Abandoned
-
2007
- 2007-01-09 CY CY20071100027T patent/CY1105912T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0202469A3 (en) | Cell adhesion inhibitor compound and pharmaceutical composition containing thereof | |
HUP0101810A3 (en) | Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them | |
IL122783A (en) | Cell adhesion inhibitors and pharmaceutical compositions containing the same | |
HUP0203378A3 (en) | Pharmaceutical compounds and pharmaceutical compositions containing them | |
IL148517A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
IL150077A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
HUP0203939A3 (en) | Pharmaceutical compounds and compositions containing them and their use | |
HUP0105113A3 (en) | Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds | |
IL139479A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
HUP0200831A2 (en) | Novel pharmaceutical composition containing amoxycillin and its use | |
IL144977A0 (en) | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
IL147970A0 (en) | Pharmaceutical compositions containing tripeptides | |
HUP0201334A3 (en) | Hydrochloride of fused-heterocycle compound and pharmaceutical compositions containing the same | |
HUP0200325A3 (en) | Pharmaceutical composition containing proton pump inhibitors | |
IL143841A0 (en) | Amide compounds and pharmaceutical compositions containing the same | |
IL149883A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
HUP0202255A3 (en) | Crystalline 1-methylcarbapenem compounds and pharmaceutical compositions containing them | |
HUP0104657A3 (en) | Imidazole compounds and pharmaceutical compositions containing them | |
HUP0002951A3 (en) | Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them | |
HUP0201714A2 (en) | Substituted heterocyclic compounds and pharmaceutical compositions containing them | |
HUP0000137A3 (en) | Controller-release pharmaceutical composition containing anangetics | |
HUP0200747A2 (en) | Pharmaceutical compounds and pharmaceutical compositions containing them | |
GB0017279D0 (en) | Amides as cell adhesion inhibitors | |
HUP0200055A3 (en) | 16-hydroxyestrienes and pharmaceutical compositions containing the same | |
HK1041270A1 (en) | 2,-3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |